

Informazione Regolamentata n. 20343-10-2025	Data/Ora Inizio Diffusione 8 Settembre 2025 17:49:11	Euronext Growth Milan
---	---	-----------------------

Societa' : OTOFARMA

Identificativo Informazione : 209751
Regolamentata

Utenza - referente : OTOFARMAESTN01 - Anna Incarnato
Bartolomucci

Tipologia : 2.5

Data/Ora Ricezione : 8 Settembre 2025 17:49:11

Data/Ora Inizio Diffusione : 8 Settembre 2025 17:49:11

Oggetto : OTOFARMA: announcement of change in
share capital following full exercise of
greenshoe option

Testo del comunicato

Vedi allegato



Press release

OTOFARMA: announcement of change in share capital following full exercise of greenshoe option

Naples, 8 September 2025 – The **Otofarma Group** – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids distributed mainly through the pharmaceutical channel – announces the new composition of its share capital following the issue of 190,500 ordinary shares of the Company relating to the full exercise of the Greenshoe Option in the capital increase (see press release of 2 September 2025) by Alantra Capital Markets S.A.U., Italian Branch (hereinafter also “Alantra”), granted by shareholder Bartolomucci Holding S.r.l. during the placement of its ordinary shares on the Euronext Growth Milan (“EGM”) market.

The new composition of Otofarma's share capital (fully subscribed and paid up) following the filing of the certificate of change in share capital with the competent Companies Register of Naples is shown below:

Current Share Capital				Previous Share Capital			Change		
	Euro	No. Shares	Nom. Value.	Euro	No. Shares	Nom. Value.	Euro	No. Shares	Nom. Value.
Total, of which	1,635,484.47	5,947,000	shares with no par value	1,583,095	5,756,500	shares with no par value	52,389	190,500	shares with no par value
Ordinary shares	1,635,484.47	5,947,000	shares with no par value	1,583,095	5,756,500	shares with no par value	52,389	190,500	shares with no par value

Pursuant to Article 26 of the Euronext Growth Milan Issuers' Regulations, the Company hereby announces the composition of its shareholding structure, updated to the latest results in its possession:

Shareholder	Number of Shares	% of Share Capital	% of Voting Rights
Bartolomucci Holding S.r.l.	4,000,000	67.26%	67.26%
Axon Partners Group SA	592,800	9.97%	9.97%
Invitalia S.p.A. (via Fondo Cresci al Sud)	381,600	6.42%	6.42%
Algebris Investments	333,300	5.60%	5.60%
Market	639,300	10.75%	10.75%
TOTAL	5,947,000	100%	100%

The shareholder structure is also available in the Shareholders section of the Company's website (www.otofarmaspa.com), under Investor Relations.



The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.

Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

About Otofarma SpA

Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.

Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.

Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.

For more information:

Otofarma S.p.A. - Investor relations

Anna Incarnato Bartolomucci

E-mail: anna.incarnato@otofarma.it

mob: +39 347 0506780

Alantra – Euronext Growth Advisor

E-mail: ega@alantra.com

mob: +39 334 6267242

SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – michele.bon@secnewgate.it – +39 338 693 3868

Francesca Brambilla – francesca.brambilla@secnewgate.it – +39 338 627 2146

Fine Comunicato n.20343-10-2025	Numero di Pagine: 4
---------------------------------	---------------------